Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.

Currie, Craig J; McEwan, Phil; Poole, Chris; Valentine, William J; Palmer, Andrew J; Lammert, Morten; Nicklasson, Lars; Foos, Volker; Roze, Stéphane

Currie, Craig J; McEwan, Phil; Poole, Chris; Valentine, William J; Palmer, Andrew J; Lammert, Morten; Nicklasson, Lars; Foos, Volker; Roze, Stéphane.

Curr Med Res Opin ; 22(5): 967-9; author reply 968-9, 2006 May.

Article in En | MEDLINE | ID: mdl-16709318

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Health Care Costs; Insulin/analogs & derivatives; Treatment Outcome; Biphasic Insulins; Cost-Benefit Analysis; Humans; Insulin/administration & dosage; Insulin/therapeutic use; Insulin Aspart; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Randomized Controlled Trials as Topic

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Treatment Outcome / Health Care Costs / Diabetes Mellitus, Type 2 / Insulin Type of study: Clinical_trials / Health_economic_evaluation Limits: Humans Language: En Journal: Curr Med Res Opin Year: 2006 Document type: Article Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links